Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.

ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.

The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.

news

> Show all

21/04/2015

ERYTECH Pharma announces the strengthening of its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent.

31/03/2015

ERYTECH réaffirme son éligibilité au PEA-PME pour 2015/2016

30/03/2015

ERYTECH provides a business update and reports its financial results for the period ending December 31, 2014.

26/03/2015

ERYTECH Pharma announces it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June.

diary

> Show all

April 27-30 2015

ERYTECH Pharma makes an oral presentation on April 30 Session 12 from 2:30 pm to 3:30 pm at CITIM 2015 congress which takes place from April 27 to 30 in Ljubljana, Slovenia.

April 18-22, 2015

ERYTECH Pharma is presenting 3 posters at ‘American Association for Cancer Research (AACR) Annual Meeting from April 18 to 22, 2015 in Philadelphie, PA, USA.

April 15-16, 2015

ERYTECH Pharma participates in BIOVISION on April 15 & 16, 2015 at Palais des Congrès in Lyon, France.

April 1-3 2015

ERYTECH Pharma presents 2 posters at Société Française d’Hématologie Annual Congress which takes place in Paris, France from April 1st to 3rd, 2015.